Femasys (NASDAQ:FEMY) COO John Charles Canning Buys 4,375 Shares

Femasys Inc. (NASDAQ:FEMY) COO John Charles Canning purchased 4,375 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $3.20 per share, with a total value of $14,000.00. Following the transaction, the chief operating officer directly owned 4,375 shares of the company’s stock, valued at approximately $14,000. This represents a ? increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Femasys Trading Down 0.8%

NASDAQ FEMY opened at $2.35 on Wednesday. Femasys Inc. has a 12 month low of $2.29 and a 12 month high of $22.20. The company has a debt-to-equity ratio of 0.53, a current ratio of 3.91 and a quick ratio of 1.98. The company has a market capitalization of $7.10 million, a price-to-earnings ratio of -0.44 and a beta of -2.08. The company’s fifty day moving average price is $3.87 and its two-hundred day moving average price is $7.49.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on FEMY shares. Wall Street Zen upgraded Femasys to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings upgraded Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $80.00.

Institutional Trading of Femasys

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Kovack Advisors Inc. acquired a new position in Femasys during the 4th quarter valued at approximately $27,000. HRT Financial LP acquired a new stake in Femasys in the fourth quarter worth $30,000. Cetera Investment Advisers acquired a new stake in Femasys in the fourth quarter worth $36,000. Osaic Holdings Inc. bought a new stake in Femasys in the second quarter valued at $45,000. Finally, State Street Corp boosted its holdings in shares of Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after acquiring an additional 24,500 shares during the period. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.